Table III.
Association of Ser326Cys polymorphism of the hOGG1 gene and Arg156Arg polymorphism of the ERCC2/XPD gene with PCa aggressiveness.
| Polymorphism genotype or allele | HR | OR | 95% CI | P-value | MR | OR | 95% CI | P-value | LR | OR | 95% CI | P-value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arg156Arg | ||||||||||||
| AA | 13 | 3.80 | 1.19–12.18 | 0.017 | 7 | 1.86 | 0.50–6.60 | 0.366 | 1 | 0.58 | 0.01–6.02 | 1.000 |
| AC | 32 | 2.48 | 1.02–6.35 | 0.033 | 13 | 0.92 | 0.34–2.54 | 1.000 | 8 | 1.24 | 0.33–5.22 | 0.773 |
| CC | 10 | 1.00 | 11 | 1.00 | 5 | 1.00 | ||||||
| AA+AC | 45 | 2.76 | 1.18–6.84 | 0.011 | 20 | 1.11 | 0.45–2.87 | 0.835 | 9 | 1.10 | 0.30–4.51 | 1.000 |
| A | 58 | 1.86 | 1.13–3.06 | 0.012 | 27 | 1.29 | 0.69–2.38 | 0.456 | 10 | 0.93 | 0.36–2.25 | 1.000 |
| C | 52 | 1.00 | 35 | 1.00 | 18 | 1.00 | ||||||
| Ser326Cys | ||||||||||||
| GG | 17 | 2.93 | 1.00–8.74 | 0.033 | 6 | 1.78 | 0.41–7.48 | 0.510 | 3 | 2.07 | 0.24–17.26 | 0.406 |
| CG | 26 | 1.10 | 0.47–2.76 | 1 | 18 | 1.31 | 0.45–4.13 | 0.637 | 8 | 1.36 | 0.30–8.51 | 1.000 |
| CC | 12 | 1.00 | 7 | 1.00 | 3 | 1.00 | ||||||
| GG+CG | 43 | 1.46 | 0.64–3.49 | 0.447 | 24 | 1.40 | 0.51–4.27 | 0.646 | 11 | 1.46 | 0.35–8.69 | 0.754 |
| G | 60 | 1.62 | 1.00–2.67 | 0.044 | 30 | 1.27 | 0.69–2.34 | 0.465 | 14 | 1.35 | 0.56–3.24 | 0.543 |
| C | 50 | 1.00 | 32 | 1.00 | 14 | 1.00 |
hOGG1, human homolog of the 8-oxoguanine DNA glycosylase 1; ERCC2/XPD, excision repair cross-complementing rodent repair deficiency complementation group 2/Xeroderma pigmentosum complementation group D; PCa, prostate cancer; OR, odds ratio; CI, confidence interval; HR, high-risk; MR, intermediate-risk; LR, low-risk.